// Post a message

Replying to:

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.

Zhang L, Wu B, Baruchel S. from the New Agent and Innovative Therapy Program, and the Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canadahave published in Translational Oncology an artivle entitled : Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.
In this article, they show using a panel of neuroblastoma cell lines carrying various ALK genetic aberrations that (…)

pre-moderation

This forum is pre-moderated: your contribution will only appear after being validated by an admin.

Who are you?
Your post

To create paragraphs, just leave blank lines.